Capital Change Notice – Performance Share Rights

Capital Change Notice

Updated as at February 2025
29 August 2025

Notice of issue of ordinary shares under Ryman’s Long Term Incentive Plan

This notice is given under NZX Listing Rules 3.13.1 and 3.15.2 and relates to the vesting of
performance share rights under Ryman’s Long Term Incentive Plan (LTIP) under which fully paid
ordinary shares in Ryman are issued on the vesting of those performance share rights.

Ryman now has 1,670,340 unlisted performance share rights (with varying vesting periods) on
issue under the LTIP.

Section 1: Issuer information
Name of issuer Ryman Healthcare Limited
NZX ticker code RYM
Class of financial product Ordinary Shares
ISIN (If unknown, check on NZX website) NZRYME0001S4
Currency NZD
Section 2: Capital change details
Number issued/acquired/redeemed 16,297 Ordinary Shares
Nominal value (if any) N/A
Issue/acquisition/redemption price per security Nil
Nature of the payment (for example, cash or other
consideration)
16,297 of the performance share rights
granted to senior executives under the
LTIP vest on 29 August 2025, and convert
into 16,297 Ordinary Shares at such time,
for no cash consideration.

These share rights were granted as part of
the transition from the previous leadership
share scheme, with time-based vesting
conditions only. Further details of the LTIP
and such performance share rights are
provided in RYM’s annual report and in its
NZX announcement of 23 September
2024.
Amount paid up (if not in full) Fully Paid
Percentage of total class of Financial Products
issued/acquired/redeemed/ (calculated on the
number of Financial Products of the Class,
excluding any Treasury Stock, in existence)
1

0.001604%
For an issue of Convertible Financial Products or
Options, the principal terms of Conversion (for
example the Conversion price and Conversion date
and the ranking of the Financial Product in relation
N/A

1
The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

to other Classes of Financial Product) or the Option
(for example, the exercise price and exercise date)
Reason for issue/acquisition/redemption and
specific authority for issue/acquisition/redemption/
(the reason for change must be identified here)
Vesting and exercise of 16,297 of the
performance share rights under the LTIP
(see details above) authorised by a board
resolution dated 29 July 2025.
Total number of Financial Products of the Class
after the issue/acquisition/redemption/Conversion
(excluding Treasury Stock) and the total number of
Financial Products of the Class held as Treasury
Stock after the issue/acquisition/redemption.
1,015,729,081 Ordinary Shares (excluding
Treasury Stock)
Nil Treasury Stock
In the case of an acquisition of shares, whether
those shares are to be held as treasury stock
N/A
Specific authority for the issue, acquisition, or
redemption, including a reference to the rule
pursuant to which the issue, acquisition, or
redemption is made
Board resolution dated 29 July 2025;
permitted under Listing Rule 4.6.1
Terms or details of the issue, acquisition, or
redemption (for example: restrictions, escrow
arrangements)
Ordinary Shares ranking equally with the
existing Ordinary Shares on issue in RYM
Date of issue/acquisition/redemption
2
29/08/2025
Section 3: Disclosure required for Placements made under Rule 4.5.1
[Issuers may opt to release Section 3 information (if not already done so) in a separate announcement within five Business Days of
the issuance. Delete this Section 3 if capital change is not the result of a Placement under Rule 4.5.1]

Details of the approach in identifying investors who
were able to participate in the offer and how their
respective allocations in the offer were determined.

The explanation must set out the key objectives
and criteria the Issuer adopted in the allocation
process, whether one of those objectives was a
best effort to allocate on a pro rata basis to existing
holders of the Issuer’s Equity Securities, and any
significant exceptions or deviations from those
objectives and criteria.
N/A
Section 4: Authority for this announcement and contact person
Name of person

authorised to make this
announcement
Morgan Powell
Contact person for this announcement Morgan Powell
Contact phone number +64 21 246 6361
Contact email address morgan.powell@rymanhealthcare.com
Date of release through MAP

29/08/2025




2
Continuous issuers using this form in reliance on Rule 3.13.2, please indicate the period during which the relevant
issue/acquisition/redemptions were made (for example, 1 January 2019 to 31 January 2019).